Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Antigen Express, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Antigen Express, Inc. - Product Pipeline Review - 2014', provides an overview of the Antigen Express, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Antigen Express, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Antigen Express, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Antigen Express, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Antigen Express, Inc.'s pipeline products Reasons to buy - Evaluate Antigen Express, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Antigen Express, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Antigen Express, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Antigen Express, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Antigen Express, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Antigen Express, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Antigen Express, Inc. Snapshot 5 Antigen Express, Inc. Overview 5 Key Information 5 Key Facts 5 Antigen Express, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Antigen Express, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Antigen Express, Inc. - Pipeline Products Glance 10 Antigen Express, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 Antigen Express, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Antigen Express, Inc. - Drug Profiles 13 AE-37 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AE-08 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AE-298p 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AE-443p 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 AEA-35p 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AEH-10p 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 DNA Vaccine for HIV 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vaccine for Acute Myelogenous Leukemia 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Vaccine for Allergy 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Antigen Express, Inc. - Pipeline Analysis 24 Antigen Express, Inc. - Pipeline Products by Target 24 Antigen Express, Inc. - Pipeline Products by Route of Administration 25 Antigen Express, Inc. - Pipeline Products by Molecule Type 26 Antigen Express, Inc. - Recent Pipeline Updates 27 Antigen Express, Inc. - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables Antigen Express, Inc., Key Information 5 Antigen Express, Inc., Key Facts 5 Antigen Express, Inc. - Pipeline by Indication, 2014 7 Antigen Express, Inc. - Pipeline by Stage of Development, 2014 8 Antigen Express, Inc. - Monotherapy Products in Pipeline, 2014 9 Antigen Express, Inc. - Phase II, 2014 10 Antigen Express, Inc. - Phase I, 2014 11 Antigen Express, Inc. - Preclinical, 2014 12 Antigen Express, Inc. - Pipeline by Target, 2014 24 Antigen Express, Inc. - Pipeline by Route of Administration, 2014 25 Antigen Express, Inc. - Pipeline by Molecule Type, 2014 26 Antigen Express, Inc. - Recent Pipeline Updates, 2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.